
|Articles|January 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Cellectar opens manufacturing facility for radiolabeled CLR1404
Cellectar opens manufacturing facility for radiolabeled CLR1404
Advertisement
MADISON, Wisconsin-Cellectar has opened its new $3.3 million radiopharmaceutical research, development, and manufacturing facility and headquarters in Madison. The facility allows Cellectar to manufacture and radiolabel its lead compound CLR1404, a phospholipid ether combined with 131Iodine, in compliance with Good Manufacturing Practices.
Articles in this issue
over 18 years ago
New tobacco product alert: Camel Snus is on the looseover 18 years ago
Blueberry punch not quite a 'knock out' blowover 18 years ago
Texas voters listen to Lanceover 18 years ago
High cost of breast MRI screening appears to be justifiedover 18 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskover 18 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caover 18 years ago
Statins during RT may lower risk of prostate ca relapseover 18 years ago
Major policy issue lies behind ODAC's Avastin decisionNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
3
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
4
Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?
5



















































